Daijiworld Media Network - New Delhi

New Delhi, Sep 25: A promising new monoclonal antibody treatment for malaria has demonstrated strong protection and safety in its first human trial, according to a study published in The Lancet Infectious Diseases. The experimental antibody, MAM01, was found to be safe, well-tolerated, and capable of preventing infection in individuals with no prior exposure to malaria.

?? What the Study Found

In a Phase 1 randomized controlled trial, none of the participants who received the highest dose (40 mg/kg) of MAM01 developed malaria parasites in their blood up to 26 weeks after being deliberately exposed to the parasite in a controlled environment.

The trial involved 37 healthy adults aged 18–50, all of whom were malaria-naive — meaning they had never bee

See Full Page